Medicines Co. (MDCO) Reports Q4 Loss of $0.61, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Medicines Co. (MDCO) Reports Completed Enrollment Target Ahead of Schedule for ORION-9 Phase 3 Trial
February 20, 2018 7:16 AM ESTThe Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks considerably ahead of its anticipated recruitment goal of 24 weeks.
ORION-9 is a double-blind, randomized multi-national Phase III trial designed to confirm the effectiveness and safety of inclisiran in heterozygous familial hypercholesterolemia patients. In the trial, patients are randomized to inclisiran 300 mg or placebo given subcutaneously on days 1, 90, 270 and 450 then followed to the end of the study at 540 days (18 months). ORION-9 is one of four pivotal phase III trials with similar designs... More
